Systemic therapy for advanced hepatocellular carcinoma
- VernacularTitle:晚期肝细胞癌的系统治疗
- Author:
Jiahao XU
1
;
Dongxu YIN
;
Yuchen LI
;
Fujie CHEN
;
Mingda WANG
;
Tian YANG
Author Information
- Keywords: Carcinoma,Hepatocellular; Precision Medicine; Therapeutics
- From: Journal of Clinical Hepatology 2024;40(11):2306-2314
- CountryChina
- Language:Chinese
- Abstract: Hepatocellular carcinoma(HCC)is one of the most common malignancies with high morbidity and mortality rates worldwide.With the advances in molecular biology and tumor immunology,molecular-targeted agents represented by tyrosine kinase inhibitors(such as sorafenib and lenvatinib)and immunotherapy represented by PD-1/PD-L1 monoclonal antibodies have brought hope for patients with advanced HCC.The combination of immunotherapy and anti-angiogenic therapy can further improve the treatment outcome of patients.In addition,the optimization and integration of stereotactic body radiotherapy,local treatment,and systemic treatment may maximize the benefits of patients.In the future,through a deep understanding of the heterogeneity of HCC,the development of precision molecular subtyping and individualized treatment,and the establishment of a multidisciplinary collaborative diagnosis and treatment system,systemic therapy is expected to achieve long-term management of advanced HCC.This article reviews the current status and advances in systemic therapy for advanced HCC.
